Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.01
Change (%) Stock is Up 0.01 (0.33%)
Volume665,710
Data as of 01/17/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
01/04/18Verastem Announces Increased Hercules Debt Facility
Increases Borrowing Limit to $50 Million Over the Next 15 Months, Through Potential Approval and Commercial Launch of Duvelisib BOSTON--(BUSINESS WIRE)--Jan. 4, 2018-- Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced its entry into an amendment to its Loan and Security Agreement with Hercules Capital, Inc., increasing its existing borrowing ... 
Printer Friendly Version
01/04/18Verastem Appoints Joseph Lobacki as Chief Commercial Officer
BOSTON--(BUSINESS WIRE)--Jan. 4, 2018-- Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Joseph Lobacki as Executive Vice President and Chief Commercial Officer. Mr. Lobacki, formerly Chief Commercial Officer of Medivation, will be responsible for overseeing the commercial strategy and execution for Verastem’s lead product candidate... 
Printer Friendly Version
12/15/17Verastem Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Dec. 15, 2017-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its previously announced underwritten public offering of approximately $25 million of shares of its common stock. All of the shares to be sold in the offering are to be sold by Verastem. BTIG, LLC is acting as sole book-running man... 
Printer Friendly Version
12/14/17Verastem Announces Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Dec. 14, 2017-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by Verastem. BTIG, LLC is acting as sole book-running manager for the offering. ... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.